Company news

Cytokinetics, Incorporated (NASDAQ:CYTK) news

Cytokinetics, Incorporated news releases on 6ix. Latest, Oct 2, 2026: Cytokinetics Announces Four Upcoming Presentations at the HFSA Annual Scientific Meeting…

Cytokinetics, Incorporated (NASDAQ:CYTK) news

Press releases & updates

Cytokinetics Announces Four Upcoming Presentations at the HFSA Annual Scientific Meeting 2026

Cytokinetics Launches ASPEN-HCM: A Real-World Study Evaluating MYQORZO® (aficamten) in Symptomatic Obstructive Hypertrophic Cardiomyopathy

Cytokinetics Launches ASPEN-HCM: A Real-World Study Evaluating MYQORZO® (aficamten) in Symptomatic Obstructive Hypertrophic Cardiomyopathy

Cytokinetics Announces Call for Proposals for Ninth Annual Communications Grant Program

Cytokinetics Announces Additional Results from ACACIA-HCM and MAPLE-HCM Presented in Late Breaking Clinical Trial Session at the European Society of Cardiology (ESC) Congress 2026

Cytokinetics Announces Upcoming Presentations at the European Society of Cardiology (ESC) Congress 2026

Cytokinetics Reports Second Quarter 2026 Financial Results and Provides Business Update

Cytokinetics Announces MHRA Marketing Authorisation for MYQORZO®▼ (aficamten) and Positive Guidance from NICE for Symptomatic Obstructive Hypertrophic Cardiomyopathy in England and Wales

Cytokinetics to Announce Second Quarter Results on August 6, 2026

Cytokinetics Announces Three Late-Breaking Science Abstracts at the European Society of Cardiology (ESC) Congress 2026

Cytokinetics Announces Call for Proposals for Annual Corporate Giving Program

Cytokinetics Launches MYQORZO® (aficamten) in European Union, with First Commercial Availability in Germany

Cytokinetics Announces New Data Related to MYQORZO® (aficamten) at ESC Heart Failure 2026

Cytokinetics Announces Closing of Public Offering of Common Stock and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $805 Million

Cytokinetics Announces Pricing of Upsized Public Offering of Common Stock

Cytokinetics Reports First Quarter 2026 Financial Results and Provides Business Update

Cytokinetics Announces Positive Topline Results from ACACIA-HCM, the Pivotal Phase 3 Clinical Trial of Aficamten in Patients with Non-Obstructive Hypertrophic Cardiomyopathy

Cytokinetics to Announce Topline Results from ACACIA-HCM, the Pivotal Phase 3 Clinical Trial of Aficamten in Patients with Non-Obstructive Hypertrophic Cardiomyopathy, on May 5, 2026

Cytokinetics Announces Nine Upcoming Presentations at the European Society of Cardiology Heart Failure 2026 Congress

Cytokinetics to Announce First Quarter Results on May 5, 2026

Cytokinetics to Participate in the 25th Annual Needham Virtual Healthcare Conference

Cytokinetics Announces Four Presentations at the American College of Cardiology Annual Scientific Session & Expo

Cytokinetics Reports Fourth Quarter 2025 Financial Results and Provides Business Update

Cytokinetics Announces European Commission Approval of MYQORZO® (aficamten) for the Treatment of Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy

Cytokinetics to Announce Fourth Quarter Results on February 24, 2026

Cytokinetics Announces Recipients of Its Eighth Annual Communications Grant Program

Cytokinetics Announces MYQORZO™ (aficamten) Now Available in the U.S. for the Treatment of Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy to Improve Functional Capacity and Symptoms

Cytokinetics and Olympic Gold Medalist Sydney McLaughlin-Levrone Team Up to Raise Awareness of the Whole-Person Impact of Hypertrophic Cardiomyopathy (HCM)

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CareMed Has Been Selected as a National Specialty Pharmacy Provider for MYQORZO™ (aficamten)

Cytokinetics to Present at the 44th Annual J.P. Morgan Healthcare Conference

Cytokinetics Announces FDA Approval of MYQORZO™ (aficamten) for the Treatment of Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy to Improve Functional Capacity and Symptoms

Cytokinetics Announces NMPA Approval of MYQORZO® (aficamten) in China for Patients with Obstructive Hypertrophic Cardiomyopathy

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Cytokinetics Announces Positive CHMP Opinion of MYQORZO® (Aficamten) for the Treatment of Obstructive Hypertrophic Cardiomyopathy

Cytokinetics Supports American Heart Association Initiative to Improve Care for People Living With Hypertrophic Cardiomyopathy

Cytokinetics Presents Additional Data from MAPLE-HCM at the Hypertrophic Cardiomyopathy Medical Society Scientific Sessions and American Heart Association Scientific Sessions 2025

Cytokinetics Reports Third Quarter 2025 Financial Results and Provides Business Update

Cytokinetics to Participate in November Investor Conferences

Cytokinetics Announces Upcoming Presentations at the Hypertrophic Cardiomyopathy Medical Society Scientific Sessions and American Heart Association Scientific Sessions 2025

Cytokinetics to Announce Third Quarter Results on November 5, 2025

Cytokinetics Presents New Data Related to Aficamten at the HFSA Annual Scientific Meeting 2025

Cytokinetics Announces Call for Proposals for Its Eighth Annual Communications Grant Program

Cytokinetics to Present at the Stifel 2025 Virtual Cardiometabolic Forum

Cytokinetics Announces Three Upcoming Presentations at the HFSA Annual Scientific Meeting 2025

Cytokinetics Announces Proposed Private Placement of $550.0 Million of Convertible Senior Notes

Cytokinetics Announces Pricing of Upsized $650.0 Million Convertible Senior Notes Offering; Refinances a Portion of 2027 Convertible Notes

Cytokinetics Presents New Data Related to Aficamten at the European Society of Cardiology Congress 2025

Cytokinetics Announces Primary Results from MAPLE-HCM Presented at the European Society of Cardiology Congress 2025 and Published in The New England Journal Of Medicine

Cytokinetics to Participate in September Investor Conferences